SARS-CoV-2 variants and COVID-19 vaccines: Current challenges and future strategies
- PMID: 35635216
- DOI: 10.1080/08830185.2022.2079642
SARS-CoV-2 variants and COVID-19 vaccines: Current challenges and future strategies
Abstract
The ongoing COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a global threat. Despite strict control measures implemented worldwide and immunization using novel vaccines, the pandemic continues to rage due to emergence of several variants of SARS-CoV-2 with increased transmission and immune escape. The rapid spread of variants of concern (VOC) in the recent past has created a massive challenge for the control of COVID-19 pandemic via the currently used vaccines. Vaccines that are safe and effective against the current and future variants of SARS-CoV-2 are essential in controlling the COVID-19 pandemic. Rapid production and massive rollout of next-generation vaccines against the variants are key steps to control the COVID-19 pandemic and to help us return to normality. Coordinated surveillance of SARS-CoV-2, rapid redesign of new vaccines and extensive vaccination are needed to counter the current SARS-CoV-2 variants and prevent the emergence of new variants. In this article, we review the latest information on the VOCs and variants of interest (VOIs) and present the information on the clinical trials that are underway on evaluating the effectiveness of COVID-19 vaccines on VOCs. We also discuss the current challenges posed by the VOCs in controlling the COVID-19 pandemic and future strategies to overcome the threat posed by the highly virulent and rapidly transmissible variants of SARS-CoV2.
Keywords: Bacillus Calmette-Guerin (BCG); COVID-19; SARS-CoV-2; mutations; vaccines; variants.
Plain language summary
The COVID-19 is a contagious respiratory disease caused by a virus known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that emerged in 2019. The COVID-19 has now spread to all part of the world and has become a global threat. Even after the strict control measures and immunization programs to prevent the disease, COVID-19 is still causing destruction due to appearance of new strains of SARS-CoV-2 that transmit faster and capable of escaping the immunity. The faster spread of the new strains of viruses that cause more severe disease is the biggest challenge to control the COVID-19 pandemic by using the presently available vaccines. To control the COVID-19 pandemic we urgently need safe and effective vaccines against the corona viral variants. This can be achieved by tracking the appearance of new viral types, design and rapid production and supply of new vaccines against the virus. This article presents the latest information on the new types of SARS-CoV-2, and on the status of vaccine trials and their effectiveness against these viruses. Similarly, the information on the challenges posed by the new viral strains in controlling the COVID-19 and future strategies to overcome the threat posed by corona viruses is also provided.
Similar articles
-
SARS-CoV2 variant-specific replicating RNA vaccines protect from disease following challenge with heterologous variants of concern.Elife. 2022 Feb 22;11:e75537. doi: 10.7554/eLife.75537. Elife. 2022. PMID: 35191378 Free PMC article.
-
The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.J Biol Regul Homeost Agents. 2021 Jan-Feb;35(1):1-4. doi: 10.23812/21-3-E. J Biol Regul Homeost Agents. 2021. PMID: 33377359
-
COVID-19 Pandemic and Vaccines Update on Challenges and Resolutions.Front Cell Infect Microbiol. 2021 Sep 10;11:690621. doi: 10.3389/fcimb.2021.690621. eCollection 2021. Front Cell Infect Microbiol. 2021. PMID: 34568087 Free PMC article. Review.
-
Evolution, Mode of Transmission, and Mutational Landscape of Newly Emerging SARS-CoV-2 Variants.mBio. 2021 Aug 31;12(4):e0114021. doi: 10.1128/mBio.01140-21. Epub 2021 Aug 31. mBio. 2021. PMID: 34465019 Free PMC article.
-
The Coming of Age of Nucleic Acid Vaccines during COVID-19.mSystems. 2023 Apr 27;8(2):e0092822. doi: 10.1128/msystems.00928-22. Epub 2023 Mar 2. mSystems. 2023. PMID: 36861992 Free PMC article. Review.
Cited by
-
The End or a New Era of Development of SARS-CoV-2 Virus: Genetic Variants Responsible for Severe COVID-19 and Clinical Efficacy of the Most Commonly Used Vaccines in Clinical Practice.Vaccines (Basel). 2023 Jun 30;11(7):1181. doi: 10.3390/vaccines11071181. Vaccines (Basel). 2023. PMID: 37514997 Free PMC article. Review.
-
Compartmental modeling for pandemic data analysis: The gap between statistics and models.Heliyon. 2024 May 22;10(11):e31410. doi: 10.1016/j.heliyon.2024.e31410. eCollection 2024 Jun 15. Heliyon. 2024. PMID: 38832260 Free PMC article.
-
Synthesis, molecular docking, and binding Gibbs free energy calculation of β-nitrostyrene derivatives: Potential inhibitors of SARS-CoV-2 3CL protease.J Mol Struct. 2023 Jul 15;1284:135409. doi: 10.1016/j.molstruc.2023.135409. Epub 2023 Mar 23. J Mol Struct. 2023. PMID: 36993878 Free PMC article.
-
Research progress on specific and non-specific immune effects of BCG and the possibility of BCG protection against COVID-19.Front Immunol. 2023 Jan 31;14:1118378. doi: 10.3389/fimmu.2023.1118378. eCollection 2023. Front Immunol. 2023. PMID: 36798128 Free PMC article. Review.
-
Ghosts of the past: Elemental composition, biosynthesis reactions and thermodynamic properties of Zeta P.2, Eta B.1.525, Theta P.3, Kappa B.1.617.1, Iota B.1.526, Lambda C.37 and Mu B.1.621 variants of SARS-CoV-2.Microb Risk Anal. 2023 Aug;24:100263. doi: 10.1016/j.mran.2023.100263. Epub 2023 May 20. Microb Risk Anal. 2023. PMID: 37234934 Free PMC article.
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous